Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Eric D. Hsi, Hongli Li, Andrew B. Nixon, Heiko Schöder, Nancy L. Bartlett, Michael LeBlanc, Sonali Smith, Brad S. Kahl, John P. Leonard, Andrew M. Evens, David W. Scott, Lisa Rimsza, Jonathan W. Friedberg

Research output: Contribution to journalArticle

Abstract

Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)-positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.

Original languageEnglish (US)
Pages (from-to)1762-1765
Number of pages4
JournalBlood
Volume133
Issue number16
DOIs
StatePublished - Apr 18 2019

Fingerprint

Chemokine CCL22
Thymus
Hodgkin Disease
Chemokines
Interleukin-10
Thymus Gland
Chemical activation
Positron emission tomography
Disease-Free Survival
Serum
Positron-Emission Tomography
Biomarkers
Viruses
Human Herpesvirus 4
Cytokines
Cellular Microenvironment
Tumor Microenvironment
Survival
Therapeutics
Tumors

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Hsi, E. D., Li, H., Nixon, A. B., Schöder, H., Bartlett, N. L., LeBlanc, M., ... Friedberg, J. W. (2019). Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood, 133(16), 1762-1765. https://doi.org/10.1182/blood-2018-08-870915

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma : a SWOG S0816 correlative study. / Hsi, Eric D.; Li, Hongli; Nixon, Andrew B.; Schöder, Heiko; Bartlett, Nancy L.; LeBlanc, Michael; Smith, Sonali; Kahl, Brad S.; Leonard, John P.; Evens, Andrew M.; Scott, David W.; Rimsza, Lisa; Friedberg, Jonathan W.

In: Blood, Vol. 133, No. 16, 18.04.2019, p. 1762-1765.

Research output: Contribution to journalArticle

Hsi, ED, Li, H, Nixon, AB, Schöder, H, Bartlett, NL, LeBlanc, M, Smith, S, Kahl, BS, Leonard, JP, Evens, AM, Scott, DW, Rimsza, L & Friedberg, JW 2019, 'Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study', Blood, vol. 133, no. 16, pp. 1762-1765. https://doi.org/10.1182/blood-2018-08-870915
Hsi, Eric D. ; Li, Hongli ; Nixon, Andrew B. ; Schöder, Heiko ; Bartlett, Nancy L. ; LeBlanc, Michael ; Smith, Sonali ; Kahl, Brad S. ; Leonard, John P. ; Evens, Andrew M. ; Scott, David W. ; Rimsza, Lisa ; Friedberg, Jonathan W. / Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma : a SWOG S0816 correlative study. In: Blood. 2019 ; Vol. 133, No. 16. pp. 1762-1765.
@article{f42be6b8dae54f4f8872407a249df4e7,
title = "Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study",
abstract = "Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)-positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.",
author = "Hsi, {Eric D.} and Hongli Li and Nixon, {Andrew B.} and Heiko Sch{\"o}der and Bartlett, {Nancy L.} and Michael LeBlanc and Sonali Smith and Kahl, {Brad S.} and Leonard, {John P.} and Evens, {Andrew M.} and Scott, {David W.} and Lisa Rimsza and Friedberg, {Jonathan W.}",
year = "2019",
month = "4",
day = "18",
doi = "10.1182/blood-2018-08-870915",
language = "English (US)",
volume = "133",
pages = "1762--1765",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma

T2 - a SWOG S0816 correlative study

AU - Hsi, Eric D.

AU - Li, Hongli

AU - Nixon, Andrew B.

AU - Schöder, Heiko

AU - Bartlett, Nancy L.

AU - LeBlanc, Michael

AU - Smith, Sonali

AU - Kahl, Brad S.

AU - Leonard, John P.

AU - Evens, Andrew M.

AU - Scott, David W.

AU - Rimsza, Lisa

AU - Friedberg, Jonathan W.

PY - 2019/4/18

Y1 - 2019/4/18

N2 - Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)-positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.

AB - Serum soluble chemokines/cytokines produced by Hodgkin cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum thymus and activation-related chemokine (TARC), macrophage-derived chemokine (MDC), interleukin-10 (IL-10), and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (PET), and after therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET (PET2)-positive patients (www.clinicaltrials.gov #NCT00822120). Epstein-Barr virus (EBV) status was assessed, and 559 serum samples were evaluated for TARC, MDC, IL-10, and sCD163 by immunoassay. EBV positivity correlated with higher sCD163 and IL-10 levels but lower TARC levels. While baseline biomarker levels were not associated with outcome, sCD163 levels at the time of PET2 were associated with favorable progression-free survival (PFS), adjusting for PET2 status. After therapy TARC, MDC, and IL-10 correlated with PFS and overall survival (OS) on univariable analysis, which remained significant adjusting for international prognostic score. When also adjusting for end-of-therapy PET results, TARC and IL-10 remained significantly associated with shorter PFS and OS. Exploratory analysis in PET2-negative patients showed that elevated posttherapy TARC and IL-10 levels were associated with PFS. Serum cytokine levels correlate with outcome in cHL and should be investigated further in risk-adapted cHL trials.

UR - http://www.scopus.com/inward/record.url?scp=85065022565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065022565&partnerID=8YFLogxK

U2 - 10.1182/blood-2018-08-870915

DO - 10.1182/blood-2018-08-870915

M3 - Article

C2 - 30723079

AN - SCOPUS:85065022565

VL - 133

SP - 1762

EP - 1765

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -